Cardio-oncology & otherRandomised controlled trial
Prospective Analysis of Immunosuppressive Therapy in Cardiac Sarcoidosis With Fluorodeoxyglucose Myocardial Accumulation
- Prospective study with randomised comparison
Authors' conclusion
The 6-month regimen of PSL was a potent therapeutic tool for active CS. When MTX was added to low-dose PSL in patients refractory to the initial PSL therapy, there was no significant difference compared with re-PSL.
Study context
- Population
- Patients with active cardiac sarcoidosis (CS) on 18F-FDG-PET56 completed initial prednisolone (PSL)
- Participants
- 59 patients
- Comparison
- Methotrexate (MTX) vs repeat PSL in patients refractory to initial PSL
- MTXn = 5
- Repeat PSL (re-PSL)n = 6reference
- Primary endpoint
- Efficacy of MTX in PSL-refractory patients assessed by cardiac metabolic activity (CMA) on 18F-FDG-PET
- Follow-up
- 6 months
Primary result
As reported in the abstract
CMA reduction
- Neither MTX nor re-PSL showed a significant reduction in cardiac metabolic activity (CMA); MTX comparable to re-PSL
Further findings
Median CMA after initial 6-month PSL regimen
- Median CMA reduced from 203.3 to 1.0
- P < 0.001
- Response
- 47
- Poor response
- 9
- Recurrent
- 2
Original publication
Prospective Analysis of Immunosuppressive Therapy in Cardiac Sarcoidosis With Fluorodeoxyglucose Myocardial Accumulation. JACC Cardiovasc Imaging. Published 12 July 2023. doi:10.1016/j.jcmg.2023.05.017
Summarised from the published abstract; every number is checked against it